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Background: Determination of HIV-1 tropism is a pre-requisite to the use of CCR5 antagonists. This study eval-
uated the potential of population genotypic tropism tests (GTTs) in clinical practice, and the correlation with
phenotypic tropism tests (PTTs) in patients accessing routine HIV care.
Methods: Forty-nine consecutive plasma samples for which an original TrofileTM assay was performed were
obtained from triple-class-experienced patients in need of a therapy change. Viral tropism was defined as
the consensus of three or more tropism calls obtained from the combination of two independent population
PTT assays (Trofile Biosciences, San Francisco, CA, USA, and Virco, Beerse, Belgium), population GTTs and
GTTs based on ultra-deep sequencing. If no consensus was reached, a clonal PTT was performed in order to
finalize the tropism call. This two-step approach allowed the definition of a reference tropism call.
Results: According to the reference tropism result, 35/49 samples were CCR5 tropic (R5) (patients eligible for
maraviroc treatment) and 14/49 were assigned as non-R5 tropic. The non-R5 samples [patients not eligible
for maraviroc treatment according to the FDA/European Medicines Agency (EMEA) label] group included both
the CXCR4 (X4) samples and the dual and mixed CCR5/CXCR4 (R5/X4) samples. Compared with TrofileTM popu-
lation PTTs, population GTTs showed a higher sensitivity (97%) and a higher negative predictive value (91%), but
almost equal specificity and an equal positive predictive value.
Conclusions: In line with recent reports from clinical trial data, our data support the use of population genotypic
tropism testing as a tool for tropism determination before the start of maraviroc.
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Introduction
Although more than 25 antiretroviral drugs within six different
classes have been approved by the US Food and Drug Adminis-
tration (FDA) and the European Medicines Agency (EMEA),
current treatment options against HIV-1 remain compromised
by broad drug cross-resistance and short- and long-term tox-
icity.1–3 The finding that several commonly prescribed antiretro-
virals, including didanosine, abacavir and ritonavir-boosted
protease inhibitors, may be associated with increased
cardiovascular risk underscores the need for drugs with an
improved safety profile.4,5 Entry of HIV-1 into lymphocytes and
monocytes requires binding of the envelope glycoprotein
(gp120) to the CD4 receptor, followed by interaction with one
of two main co-receptors, CCR5 or CXCR4. The preferential use
of CCR5 or CXCR4, called viral tropism, is mainly determined by
the amino acid sequence of the V3 region of gp120, although
regions outside V3, such as V1/V2, C4 and the bridging sheet,
may also be involved.6 Strains that use the CCR5 co-receptor
are called CCR5-tropic or R5 viruses, those that use CXCR4 are
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labelled as CXCR4-tropic or X4 viruses. Dually tropic strains can
use both CCR5 and CXCR4 and are known as R5/X4 viruses. As
the CD4 cell count starts to drop in patients with late stage
HIV-1 infection, the prevalence of X4 or R5/X4 strains rises
within the viral quasi-species, and starting from a minority popu-
lation, these strains can finally emerge as a majority population.7
Maraviroc is the first CCR5 antagonist to receive FDA and EMEA
approval. Determination of viral tropism is a prerequisite to the
use of these CCR5 antagonists. Several techniques to determine
HIV-1 tropism have been developed over the years, including
phenotypic and genotypic methods, which show varying
degrees of correlation in direct comparisons. A diagnostic gold
standard is currently lacking. Among the phenotypic tropism
tests (PTTs), the TrofileTM assay (Monogram Biosciences,
San Francisco, CA, USA) in its original version was used for the
prospective recruitment of patients within clinical trials.8 The
original TrofileTM assay (OTA) allowed detection of CXCR4-using
strains with a sensitivity approaching 100% at a prevalence of
≥10% of the quasi-species in clonal mixtures.9 A more sensitive
assay version, the ‘enhanced sensitivity TrofileTM assay’ (ESTA)
increased the sensitivity of detection down to 0.3%, again
based on mixtures of viral clones.10 Another PTT has been devel-
oped by Virco (Beerse, Belgium) for research purposes only.11
This assay was able to detect CXCR4-using strains in clinical
samples when present at ≥10% of the quasi-species.12 It
should be noted, however, that the optimal sensitivity of detec-
tion of CXCR4-using virus for effectively guiding clinical practice
has not been conclusively determined.
Co-receptor use can also be predicted based on the amino
acid sequence of the gp120 V3 loop using several publicly avail-
able interpretation algorithms.13,14
Among these, Geno2Pheno[coreceptor] uses a support vector
machine statistical learning model. Geno2Pheno has been
designed by taking mainly genetic and phenotypic information
derived from HIV-1 subtype B into consideration. The recent intro-
duction of the 454 technology for ultra-deep sequencing offers a
new opportunity for characterizing the viral quasi-species by gen-
erating several thousands of sequences from each sample,15–17
thus allowing the fine characterization of drug-resistance
patterns.15,18
According to the FDA and EMEA labels, maraviroc can be used
only in patients with R5 virus. In the registration trials, the OTA
was used for PTTs. The OTA, however, is no longer available, as
it was replaced by the ESTA in July 2008. Current consensus
from the European, British and German–Austrian guidelines for
tropism testing indicate that tropism determination can be per-
formed by a PTT or genotypic tropism test (GTT).19–21 The sup-
porting evidence for the GTT as an acceptable alternative to
the PTT, and for ESTA as a valid PTT assay, has been mainly
derived from retrospective evaluations of patients enrolled in
clinical trials.10,22,23 The goal of this study was to evaluate the
usefulness of an academic developed population GTT in compari-
son with the OTA (assay available at the time of sampling) in an
independent dataset in routine clinical practice.
Methods
Study subjects and clinical samples
Plasma samples were collected from 49 patients eligible for maraviroc
initiation, for which an OTA was performed. Patients were selected
from the maraviroc expanded access programme in three Belgian AIDS
Reference Centres (Institute for Tropical Medicine, Antwerp; Centre Hospi-
talier Universitaire Saint-Pierre, Brussels; and University Hospital, Liege),
the Royal Free Hospital HIV Centre and Wharfside Clinic, St Mary’s Hospi-
tal (London, UK) between 1 October 2007 and 31 December 2008.
Patients were triple-class experienced, with advanced HIV disease
(median CD4 nadir count 133 cells/mm3) and with a median HIV-1
RNA load of 80 000 copies/mL at the time of tropism testing. Patients
were included within the maraviroc expanded access programme (http://
clinicaltrials.gov/ct2/show/NCT00426660). Optimized background regi-
mens were guided by drug resistance testing. Informed consent was
obtained from all patients enrolled, and the study was approved by the
Ethics Committee of the University Hospital, Ghent, Belgium. Samples
were stored in aliquots at 2808C until further processing. Plasma HIV-1
RNA was quantified with the Amplicor HIV Monitor v1.5 test (Roche Diag-
nostics Systems, Basel, Switzerland) with a lower limit of detection of
50 RNA copies/mL.
Definition of the reference tropism result (RTR)
The RTR was defined in two steps. In the first step, the RTR criteria were
met if the combination of four different assays showed concordance
between at least three of the four assays. The four assays comprised:
(i) the Virco population PTT (VpPTT), which uses the NH2-V4 fragment
of gp120 on the Antivirogramw platform; (ii) the OTA, which uses the
gp160 envelope gene on a PhenoSense platform; (iii) GTT by ultra-deep
pyrosequencing on the 454 platform (UDSGTT) (454 Life Sciences,
Branford, CT, USA), combined with interpretation provided by the Geno2-
Pheno bio-informatic tool (http://coreceptor.bioinf.mpi-inf.mpg.de/index.
php); and (iv) GTT by population sequencing (PGTT), combined with the
Geno2Pheno bio-informatic tool. In the second step, discordant
samples that did not reach the criteria of three or more concordant
results were analysed using clonal PTT of up to 24 clones in order to
allow a final tropism call.
According to the RTR, results were reported as R5 (patients eligible for
maraviroc treatment) and non-R5 tropic (patients not eligible for mara-
viroc treatment according to the FDA/EMEA label). The non-R5 group
included the CXCR4 (X4) and the dual and mixed tropic samples.
V3 haplotype
The term V3 haplotype was used to describe a viral population represent-
ing individual viruses with an identical V3 sequence fragment.
VpPTT
The assay was performed as described by Van Baelen et al.11 Following
RNA extraction, the gp120 NH2-V4 region was amplified in a one-step
RT–PCR. The purified NH2-V4 amplicons were recombined with an
HIV-1 backbone deleted for gp120 NH2-V4. Recombinant plasmids
were transfected into 293T cells. The generated virus stocks were used
for infection of U87-CD4-CXCR4 and U87-CD4-CCR5 cells. Infection was
evaluated by fluorescence readout. Results were reported as R5,
non-R5 or failure.
Virco clonal phenotypic tropism testing
The assay was performed essentially as the VpPTT assay, but the starting
material consisted of plasmids containing a clonal amplicon of NH2-V4.
Results were reported as R5, X4 or dual tropic (D), or not viable.
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OTA
Clinical samples were collected as part of routine patient management
and sent to Monogram Biosciences for tropism testing.8 Results were
reported as R5, non-R5 or failure.
UDSGTT
The assay was performed as described by Vandenbroucke et al.24 In
summary, viral RNA was extracted from 256 mL of plasma and reverse
transcribed into cDNA, then the V3 loop was amplified in a nested PCR
using bar-coded primers (HXB2 positions: forward primer 6986–7012,
reverse primer 7520–7540). To maximize the number of input templates
and to minimize variation due to PCR drift, seven parallel RT–PCRs were
performed and pooled for each sample.25 Bar-coded amplicons were
equimolarly pooled and sequenced on the 454 GS-FLX instrument
according to the manufacturer’s amplicon sequencing protocol (454
Life Sciences, Roche Diagnostics Systems). Hidden Markov models were
applied for alignment of the V3 loop. V3 amino acid sequences were
used for tropism prediction. The statistics on the sequence-read
numbers from the combined 49 clinical isolates were as follows:
average+SD ¼ 11 836+341 (range 2279–21 220). Prediction of the
co-receptor tropism was performed using the clonal Geno2Pheno predic-
tion algorithm (http://coreceptor.bioinf.mpi-inf.mpg.de/index.php) with a
false positive rate (FPR) of 5%.26 The following calls were generated:
with ,5% of the virus population labelled X4 (expressed by the total
number of sequencing reads), the sample was considered R5; with
.5% of the virus population as a mixed tropic, the sample was con-
sidered non-R5.
PGTT
RNAwas extracted from 200 to 500 mL of plasma using the High Pure Viral
RNA Kit (Roche Diagnostics Systems). Elution was performed with 50 mL of
elution buffer. Nested-PCR amplification of a fragment spanning the V1 to
V4 region of the env gene was performed (HXB2 primer positions: outer
PCR, forward primer 6540–6560 and reverse primer 7701–7721; and
inner PCR, forward primer 6561–6580 and reverse primer 7645–7667).
Table 1. Overview of tropism assignment according to the two-step approach and concordance of (i) VpPTT; (ii) OTA; (iii) UDSGTT; and (iv)
PGTT
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Grey shading indicates samples for which at least one assay failed.
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Sequencing reactions were prepared using the BigDyew Terminator Cycle
Sequencing kit v3.1 (Applied Biosystems, Foster City, CA, USA) with degen-
erate internal primers: sense 5′-AGYRCAGTACAATGYACACATGG-3′; sense
5′-TCAACHCAAYTRCTGTTAAATGG-3′; and antisense 5′-ATTTCTGGRT
CYCCKCCTG-3′. Sequencing productswere run on anABI3130xl automated
sequencer. Sequence editing and contig assembly were performed using
the SmartgeneTM HIV software package (Integrated Database Network
System, Smartgene, Zug, Switzerland). V3 nucleic acid sequences were
used for tropism prediction with the clonal Geno2Pheno prediction algor-
ithm using an FPR of 5%.
Results
Results of four tropism assays
Results of the four assays are summarized in Table 1. Samples
were divided into subgroups according to the individual
test results (in the following order: VPPTT/OTA/UDSGTT/PGTT):
A ¼ R5/R5/R5/R5; B ¼ non-R5/non-R5/non-R5/non-R5; C ¼ R5/
non-R5/R5/R5; D ¼ R5/non-R5/non-R5/non-R5; E ¼ non-R5/
R5/non-R5/non-R5; F ¼ non-R5/non-R5/non-R5/fail; G ¼ R5/fail/
R5/R5; H ¼ non-R5/fail/non-R5/non-R5; I ¼ fail/R5/R5/R5
(samples were categorized as showing concordance in at least
three assays); J ¼ R5/R5/non-R5/fail; K ¼ R5/R5/non-R5/non-R5;
L ¼ non-R5/non-R5/R5/R5; M ¼ R5/fail/non-R5/R5; and N ¼ non-
R5/fail/non-R5/R5 (samples were categorized as lacking concor-
dance in at least three assays).
Samples showing concordance in at least three assays
In the groups A–I, at least three assay test results could be
obtained. For these samples, a detailed analysis was performed
of the discordant call. In group C, three samples were non-R5 by
OTA but R5 by the other three assays. The ultra-deep sequencing
assay did not detect X4 strains in two of the three samples, and
detected a low prevalence (1.6%; but because the cut-off of 5%
labelled as R5 only) of X4 strains in the third sample. Thus, the
final call for group C favoured R5. In group D, one sample was
R5 by VPPTT but non-R5 by the other three tests. The ultra-deep
sequencing assay identified 46% X4 strains. Thus, the final call
for group D favoured non-R5. In group E, two samples were R5
by OTA but non-R5 by the other three tests. The ultra-deep
sequencing assay identified 24% and 65% X4 strains. Thus, the
final call for group E strains favoured non-R5.
Samples lacking concordance in at least three assays
With samples lacking concordance in three or more assays,
clonal phenotyping was performed to gain further insights
into the discrepancies (see Table 2). In group J, one sample
was R5 by VPPTT and OTA, whereas UDSGTT detected 16% X4
strains, while no result was obtained by PGTT. By UDSGTT,
three different populations (present .5%; haplotypes 1–3)
could be distinguished. In one population representing 11%
X4 virus of the total population by UDSGTT, clonal phenotyping
determined three clones as dual tropic, classifying the sample
as non-R5. The subgroup K sample was classified R5 by both
VPPTT and OTA, but X4 by UDSGTT (77% X4 strains) and PGTT.
Of the three populations, two (haplotypes 1 and 2; both repre-
senting+36% of the population) were classified X4 by the G2P
prediction tool. However, both populations harboured one or Ta
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more R5 clones determined by clonal phenotyping and no X4
or dual tropic clones. These data suggest that the prediction
tool is making an error both on a population as well as on
a UDSGTT level. The final call for this sample is R5. The group
L sample was non-R5 by both VPPTT and OTA, but R5 by
both UDSGTT and PGTT. The two major populations representing
haplotype 1 (14.9%) and haplotype 2 (82.3%) were classified
R5 by G2P both on a UDSGTT and population genotype level.
The clonal phenotyping determined 20 clones as dual tropic
from the major population representing 82.3%. Again these
data suggest that the prediction tool is making an error
both on a population as well as on an UDSGTT level, which
might be due to the relatively uncommon subtype (18_cpx).
The final call for this sample is non-R5. In group M, one
sample was R5 by VPPTT and PGTT, but non-R5 (5.2% X4) by
UDSGTT. In clonal phenotyping, 20 clones were classified R5,
and no X4 clones were detected. The final call for this
sample was R5. Of the three major populations, one popu-
lation representing 5.2% was not picked up by the clonal phe-
notyping. Although 20 viable clones were analysed, the clonal
phenotyping has a detection limit of around 5% and it cannot
be ruled out that the 5.2% virus population was therefore not
picked up by the random sampling (see Table 2). In group N,
one sample was non-R5 by VPPTT and UDSGTT (10.2% X4),
but was R5 by PGTT. By UDSGTT, three different major popu-
lations (.5%) could be distinguished. In one population (hap-
lotype 1) representing 9.3% X4 virus of the total population by
UDSGTT, clonal phenotyping confirmed this population as dual
tropic, classifying the sample as non-R5. The final conclusion
of the combination of first-step and second-step analysis
was that 35 samples were classified as R5 and 14 samples
as non-R5 (Table 1).
Parameters of phenotyping and genotyping methods
using RTR
By using the RTR, sensitivity and specificity of the VPPTT, OTA,
UDSGTT and PGTT could be calculated, as shown in Table 3. The
higher failure rate of the OTA affected the negative predictive
value. In general, the sensitivity of the OTA, UDSGTT and PGTT
was within the same range.
We evaluated the approximate limit of detection for minority
variants using PGTT. Only a few samples harboured a population
present between 10% and 25%, which is the estimated detec-
tion cut-off for minority variants for population genotyping
methods. Therefore, it is hard to come up with a well-defined
cut-off from this study. If the minority population drops below
10% the PGTT is not picking up this population, as is shown for
sample N (X4 present as 9.3% minority), whereas if the popu-
lation is above 10% the PGTT is picking up the population
(group H, sample with 01_AE subtype, X4 present at 12.5% of
the total population).
Subsequently the impact of the HIV subtype on the OTA and
PGTT was evaluated. In general, discordances for both the OTA
and PGTT are evenly distributed between B and non-B subtypes,
but the number of patient samples included was too small to
draw conclusions (see Table 1). The concordance with the RTR
was 31/36 (86%) for OTA and 34/36 (94%) for PGTT. Of the five
discordant OTA samples (C and E), four were subtype B. Of the
two discordant GTT samples (K and L), one was subtype B.
Clinical decisions based on OTA
In order to better understand the potential value of the different
tropism tests, we performed a theoretical evaluation of the
impact of using OTA versus PGTT for guiding clinical decisions
(see Figure 1). OTA classified 31/49 samples as R5, allowing 31
patients to start a chemokine receptor antagonist as part of
their treatment regimen. According to the definition of reference
result described previously, 28 of the 31 samples were correctly
identified as R5. Assuming use of PGTT instead of OTA, a total of
36 patients would have been returned as R5, leading to mara-
viroc use, and of these, 34 could be considered as correctly ident-
ified as R5. The net result of adopting PGTT as a diagnostic tool
would be to allow an additional five patients to receive mara-
viroc. Conversely, two patients would have started maraviroc in
the presence of X4.
According to the reference tropism test, a total of 35 patients
would have been eligible for maraviroc therapy. These 35 eligible
individuals were distributed in the OTA results as follows: 28 in
the R5 cohort, 4 from the OTA failures and 3 from the non-R5
cohort. Hence, a total of seven patients missed the opportunity
to be treated with a co-receptor antagonist, while another
three were labelled as candidates for such treatment while
non-R5 virus was present.
Similarly, the 35 eligible individuals were distributed in the
PGTT results as follows: 34 in the R5 cohort and 1 from
the non-R5 cohort. This would result in one patient missing the
opportunity to be treated with a co-receptor antagonist, while
another two were labelled as candidates for such treatment
while X4 virus was present (Table 1).
Discussion
In our study, 35 of the 49 plasma samples were classified R5
according to PGTT and 31 samples were classified as R5 accord-
ing to OTA. If samples for which one assay failed (groups F, G, H,
I, J, M and N) were ignored, concordance for all four assays was
achieved in 28/36 samples (77%). The concordance with the RTR
was 31/36 (86%) for OTA and 34/36 (94%) for pGTT. Discordant
results can be attributed to several reasons. In group C, three
plasma samples were R5 by PGTT and VPPTT, but non-R5 by
OTA. In ultra-deep sequencing, G2P scored 0% of the reads as
X4 in two samples. Thus, the FPR of OTA seems to be higher
than 0%. Indeed, the only reported FPR was measured using
plasma samples of other non-retroviruses.8 Another factor that
might have driven discordances is that OTA was running as a
routine diagnostic test and the other tests were performed retro-
spectively in a research setting. In other cases, variability of
detection at the lower end of assay sensitivity may explain the
discrepancy. One sample in group C was R5 by PGTT and VPPTT,
but non-R5 by OTA, and ultra-deep sequencing detected 1.6%
X4 reads, not accounted for because of the cut-off of 5%.
Although it is generally accepted that the detection of minorities
is superior for ultra-deep sequencing, the clonal phenotyping
was used to generate the final call. By doing this we allowed
for the pick up of potential errors in the interpretation tool that
would classify both the population and ultra-deep V3 loop
sequences identical. In both samples K and L the G2P interpret-
ation algorithm is making a different interpretation than the
clonal phenotype. In these two samples, it is not a question of
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whether or not the ultra-deep sequencing has a better sensitivity
for the detection of minorities than the clonal phenotyping, as
the populations for which the G2P differs are not present as a
minority, but as a majority. The high sensitivity for minority
detection of X4 variant by UDSGTT could be of value for the
tropism determination of sample M, now classified as R5, as
the 5.2% UDSGTT determined X4 could easily be missed by the
clonal phenotyping of 24 clones.
A further item arises from the interpretation of sequencing
results analysed, especially for rare and complex sequences. In
our analysis, if we excluded the samples where one assay
failed, the results of the PGTT analysis could not be confirmed
by RTR for samples K (subtype B) and L (18_cpx). The results of
the OTA could not be confirmed by the RTR for samples C and
E (subtype B, n ¼ 4; 13_cpx, n ¼ 1). Although the ESTA is now
performed with new primers that improve tropism prediction
Combined results of the 
following analytic tools:  
1) VpPTT  
2) OTA  
3) UDSGTT   
4) pGTT 
R5: n = 35 number of 
patients eligible for 
MVC Tx  
Non-R5: n = 14 number 
of patients ineligible 
for MVC Tx  
Clinical isolates n = 49 
Original TrofileTM was used for
clinical management 
RTR Alternative approach using 
V3 loop genotyping + G2P 
5% FPR 
Clinical isolates n = 49 
non-R5:
n = 11
non-R5:
n = 11
Patients missing the
opportunity for MVC Tx: n = 7 
Patients treated with MVC
while non-R5: n = 3  
Patients missing the
opportunity for MVC Tx: n = 1
Patients treated with MVC
while non-R5: n = 2
R5:
n = 31
R5:
n = 36
OTA
unsuccessful: 
n = 7
Sequence not 
interpretable:
n = 2
Eligible for
MVC Tx:
n = 36  
Correct 
according to 
RTR: n = 34
Tested eligible 
for MVC Tx: 
n = 31
Correct 
according to 
RTR: n = 28   
Figure 1. Overview of the study. RTR, reference tropism result; MVC, maraviroc; Tx, treatment.
Table 3. Characteristics of the genotypic and phenotypic assays
OTA VpPTT UDSGTT PGTT
RTR N R5 non-R5 F R5 non-R5 F R5 non-R5 F R5 non-R5 F
R5 35 28 3 4 31 0 4 33 2 0 34 1 0
non-5 14 3 8 3 2 12 0 1 13 0 2 10 2
Total 49 31 11 7 33 12 4 34 15 0 36 11 2
PPV 90.3 93.7 97.1 94.4
NPV 72.7 100 86.7 90.9
Sensitivity 90.3 100 94.3 97.1
Specificity 72.7 85.7 92.9 83.3
Availability replaced by ESTA not available in core facilities local, home brew protocol
Regulatory
level
CAP/CLIA research only research only dependent on local settings
TAT .3 weeks not relevant 2 weeks days
Cost moderate to high not relevant moderate to high low
TAT, turnaround time; CAP/CLIA, College of American Pathologists/Clinical Laboratory Improvement Act; PPV, positive predictive value; NPV, negative
predictive value; RTR, reference tropism result.
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on non-B viral strains, the impact of introducing this new assay
with adapted primers might have had a minor influence on the
concordance with the RTR, as most samples were subtype B.27
In this study we evaluated the potential value of population
genotyping in clinical practice. Importantly, 36 patients could
have started and benefited from maraviroc. Detailed analysis
suggests that 33 of these 36 patient samples did indeed harbour
,5% dual or mixed tropic virus, which is associated with a good
response to therapy, shown in a previous analysis by McGovern
et al.22 Our data support the findings reported earlier from the
International HIV Drug Resistance Meeting 2010 indicating that,
in treatment-experienced patients, population genotyping is com-
parable in predicting clinical outcome and response to chemokine
receptor antagonist independent of the use of the G2Por position-
specific scoring matrix (PSSM) interpretation algorithm with the
OTA.28 Our data represent the first dataset in clinical practice
where V3 loop tropism determination has been assessed outside
the context of aclinical trialwith subsequentdetailed454analysis.
In linewith the recent European, British andGermanguidelines,we
provide furtherdata to support that populationV3 loopgenotyping
is comparable to OTA in predicting tropism in clinical practice.19–21
Population V3 loop genotyping can serve as a tropism determi-
nation tool, but full standardization of the sequence method and
interpretation remains a requirement. Although our study evalu-
ated two phenotypic assays, population sequencing and ultra-
deep V3 loop sequencing, and for some discordant samples also
clonal phenotyping, results should be interpreted with caution,
as this is a retrospective evaluation of PGTT on a limited number
of samples. Prospective evaluation of PGTT in clinical practice
remains a topic of further research.
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